Other languages Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
13.73 ^USD	-3.72%		-11.30%	+28.32%

04-25	Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	CI
04-15	Guggenheim Starts Immunome With Buy Rating, $35 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	04-25
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	03-24
Immunome Closes $230 Million Public Offering	02-16
Sector Update: Health Care Stocks Gain Late Afternoon	02-06
Top Midday Gainers	02-06
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	02-06
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations	02-01
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	01-08
Immunome Appoints Phil Roberts as Chief Technical Officer	01-04
Immunome Appoints Phil Roberts as Chief Technical Officer	01-04
Immunome, Inc. Announces Board Changes	01-02
Immunome, Inc. Announces Executive Changes, Effective January 2, 2024	12-29
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	12-26
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating	12-19
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors	11-08
Immunome Appoints Bob Lechleider as Chief Medical Officer	23-10-19
Immunome Insider Bought Shares Worth $999,996, According to a Recent SEC Filing	23-10-04
Immunome Insider Bought Shares Worth $249,993, According to a Recent SEC Filing	23-10-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immunome, Inc.

Equities

IMNM

US45257U1088

Other languages

Filters